Targeting Chronic Inflammation
to Treat Neurodegeneration and Inflammatory Diseases by Inhibiting the Activity of the NLRP3 Inflammasome
At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Founded in 2017, our incredible team of scientists has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.
In The News
Dr David Bearss Discusses FDA and Safer Cancer Drugs
For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators...
Halia Therapeutics Joins Forces with Southern Star Research Pty Ltd to Advance Clinical Development of Novel LRRK2 Inhibitor, HT-4253 for Neurodegenerative Diseases
LEHI, Utah , Sept. 3, 2024 /PRNewswire/ -- Halia Therapeutics, Inc. (Halia), a clinical-stage...
Halia Therapeutics’ CEO, Dr. David J. Bearss, to Present Groundbreaking Research on Chronic Inflammation and Aging at the 3rd Edition Global Longevity Federation
Lehi, UT, August 6th, 2024/PRNewswire/ – Halia Therapeutics, a clinical-stage biopharmaceutical company, today...
We Are Experienced in Drug Discovery for Oncology and Neurodegeneration
Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer’s disease, and other neurodegenerative disorders, and we leverage these experiences to identify novel targets to treat these diseases.
Halia Pipeline
NEK7
INHIBITORS
LRRK2
INHIBITORS
Discovery | INDEnabling | Phase 1 | Phase 2 | Phase 3 |
- Oral Systemic Multiple Indications 86%
- 86%
- Ophthalmology 40%
- Gastroenterology 40%
- Neuroinflammation 34%
- Dermatology 20%
- Intervertebral Disc Disease 20%
- Alzheimer's Disease 41.5%
- Parkinson's Disease 27%
HT-6184 Lower-Risk Myelodysplastic Syndromes (LR-MDS) (Clinical Trial CTRI/2023/11/059758)
HT-6184 Post-Procedure Diagnostic Biomarkers of Inflammation and Pain (Clinical Trial NCT06241742)
HT-6184
HT-6258
HT-6283
HT-6515
HT-6153
HT-4253
HT-4403
MDS
Inflammatory Pain
IND 2024
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315